Survey

How does your health system handle new drug approvals?

1) We have a 6-month moratorium on newly FDA-approved drugs.

2) We have a 12-month moratorium on newly FDA-approved drugs.

3) If approved by the P&T committee, newly FDA-approved drugs can be added at anytime without restrictions.

4) If approved by the P&T committee, newly FDA-approved drugs can be added at anytime with step therapy or other modality to manage drug use and cost.

5) Other

Digital Edition

Vaccine may help patients avoid herpes zoster recurrence

Recurrences of herpes zoster may be more common in immunocompetent adults than once thought, according to a study published in the February issue of Mayo Clinic Proceedings, as reported in Newswise. Read full article.

FDA approves vaccine for meningococcal disease in children

FDA has approved a vaccine for preventing meningococcal disease in children. Read full article.

FDA approves drug to prevent premature births

FDA has approved hydroxyprogesterone caproate injection (Makena [formerly known as Gestiva], Hologic and KV Pharmaceutical Co.), the first drug to help prevent premature delivery before 37 weeks in women who have had at least 1 previous preterm birth. Read full article.

FDA issues CRL for Contrave

FDA has issued a complete response letter for Orexigen’s and Takeda’s Contrave (naltrexone HCl/bupropion HCl) extended-release tablets for the treatment of obesity, including weight loss and maintenance of weight loss. Read full article.

THERAPY UPDATE

A review of peripherally acting
mu-opioid receptor antagonists

This article reviews the emerging class of peripherally acting mu-opioid receptor antagonists and provides insight on formulary considerations when evaluating these agents. Read full article.

Contact Us

Contact a Formulary editor Click Here
Contact a Formulary sales representative Click Here
Learn about direct mail, reprints and classifieds in Formulary Click Here

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.